Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aflibercept + umedaptanib pegol
- Development stage
- Unknown
- Lead developer
- Ribomic
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravitreal
01
Overview
A combination therapy consisting of aflibercept, an anti-VEGF agent, and umedaptanib pegol, an anti-FGF2 aptamer. This combination was investigated for the treatment of neovascular age-related macular degeneration (nAMD), targeting both angiogenesis and fibrosis pathways simultaneously.
02
Targets
VEGFB (Vascular endothelial growth factor B)FGF2VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on aflibercept + umedaptanib pegol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aflibercept + umedaptanib pegol.